

ImmunoPrecise Antibodies Ltd

01:00 06 Dec 2019

ImmunoPrecise Antibodies is expanding its therapeutic offerings as a global full-service antibody provider

- Biotechnology company that provides state-of-the-art therapeutic antibody discovery across the entire pipeline
- Offers a complete portfolio of antibody discovery, characterization, and production technologies
- World's only single-source contract resource organization to offer the full complement of antibody discovery platforms

What ImmunoPrecise does:

Biotech company ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) provides custom antibody development and production services and protein Expression for research and development.

Its aim is to produce these therapeutically relevant antibodies, in a shorter period of time, with the highest probability of progressing to clinical trials.

Since its inception in 1989, ImmunoPrecise has been serving clinical research and biological markets worldwide. Its customers are pharma and biotech companies as well as non-profit research: universities, medical charities and grant-funded collaborations.

The company operates from a state-of-the-art laboratory at the Vancouver Island Technology Park in Victoria, British Columbia, which house its tissue culture and B-cell screening facilities, as well as an animal care unit.

It has subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands.

ImmunoPrecise wants to emulate the success of Invitrogen, which became Life Technologies before being taken over by Thermo Fisher for US\$13.6 billion. Invitrogen's bedrock business was selling kits for molecular cloning, but a series of well-judged acquisitions transformed it into the go-to supplier to the biotechnology industry.

ImmunoPrecise, which has been around for 25 years but only listed on the Toronto Venture Exchange in 2016, is at the start of a similar journey.

Its services are in high demand, given the changes in the multi-billion-dollar drugs business over the last decade. There has been a shift from the screening of traditional small-molecule chemical pharmaceuticals to bespoke biologicals, many of which are monoclonal antibodies (MABs) designed to safely and effectively tackle cancer, rheumatoid arthritis and even psoriasis.

In the US, insurers have shown a willingness to pay for the treatments, which tend to be quite expensive, while patients are demanding best-in-class biologicals that are highly targeted for grievous diseases and generally less toxic.

Price: 9.45

Market Cap: \$158.4 m

1 Year Share Price Graph



December 2019 June 2020 December 20

Share Information

Code: IPA

Listing: TSX-V

52 week	High	Low
	15.7	2.5

Sector: Pharma & Biotech

Website: immunoprecise.com

Company Synopsis:

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

action@proactiveinvestors.com

How is it doing:

ImmunoPrecise saw revenue more than double year over year for the 12 months ended April 30 to \$10.9 million from \$5.4 million thanks to its earlier acquisition of ModiQuest Research, now known as IPA Europe.

The company has also designed a platform to discover the wild-type and fully human components of bispecific antibodies, which means it can generate pairs of bound proteins with antibody backbones and the attributes necessary to bind to molecules.

The Abthena platform meshes with Artemis Intelligence Metadata, which offers rapid turnaround on additional algorithmic outputs regarding therapeutic optimization, stability, affinity and manufacturability of the antibodies.

In September, Talem Therapeutics announced a new collaboration with clinical-stage biopharmaceutical company AgonOx to develop therapies that use the body's immune system to fight cancer.

It also inked a deal with Ligand Pharmaceuticals (NASDAQ:LGND) for its novel OmniAb platform that allows Talem to access OmniAb to use with its own antibody discovery capabilities.

Inflection points:

- Expansion of animal facilities to propel preclinical capabilities
- Potential NASDAQ listing
- Opening of US research and manufacturing facilities, and US expansion for business development
- Open to partnerships and collaborations with pharma (outside of fee-for-service)

What the boss says:

In a statement accompanying ImmunoPrecise's most recent financial results, CEO Jennifer Bath commented: "We continue to expand our therapeutic offerings as a global, full-service antibody provider to pharmaceutical and biotech companies internationally, and to accelerate our volume of large-scale, therapeutic programs.

"Simultaneously, IPA sets itself on a path of Antibody Discovery and IP estate-building through Talem Therapeutics, which will expand our clinical partnerships and continue to build our IP estate."

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).